Regenetp (STU:NJT) ROCE % : -102.96% (As of Mar. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Regenetp ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Regenetp's annualized ROCE % for the quarter that ended in Mar. 2023 was -102.96%.

Regenetp ROCE % Historical Data

The historical data trend for Regenetp's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp ROCE % Chart

Regenetp Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-159.37

-151.47

-99.42

-98.78

-34.31

Regenetp Quarterly Data
	Apr18	Jul18	Oct18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
ROCE %	Get a 7-Day Free Trial															-61.57	-0.93	-64.21	-11.89	-102.96

Regenetp ROCE % Calculation

Regenetp's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-7.384	/	( ( (27.593 - 4.167)	+	(21.568 - 1.951) )	/ 2 )
	=	-7.384	/	( (23.426	+	19.617)	/ 2 )
	=	-7.384	/	21.5215
	=	-34.31 %

Regenetp's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Dec. 2022 )		(Q: Mar. 2023 )
	=	-17.732	/	( ( (21.568 - 1.951)	+	(16.858 - 2.029) )	/ 2 )
	=	-17.732	/	( ( 19.617	+	14.829 )	/ 2 )
	=	-17.732	/	17.223
	=	-102.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

Regenetp (STU:NJT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Regenetp ROCE % Related Terms

Thank you for viewing the detailed overview of Regenetp's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (STU:NJT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RGTPQ:USA

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines